CG-P5

VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration (wAMD) CG-P5 is the world's first VEGFR2-inhibiting peptide formulated as a topical eye drop for the treatment of wet agerelated macular degeneration (wAMD). Unlike intravitreal anti-VEGF injections (e.g., Eylea, Lucentis), CG-P5 delivers therapeutic effect via a non-invasive topical route, significantly enhancing patient convenience and compliance while minimizing risks associated with ocular injections.